Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SER-262 in Primary CDI
NCT02830542Phase 1Completed
- Sponsor
- Seres Therapeutics
- Start
- Aug 2016
- Primary completion
- May 2018
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Clostridioides difficile infection (CDI) comparing SER-262 with Placebo (2 arms). Primary endpoints: Safety and tolerability of SER-262 at 24 weeks and Relative risk of recurrence at 8 weeks. Started Aug 2016; status: completed.
02
Drugs
SER-262
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02830542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02830542.